Latest At 10 years, the disease-free survival rate was 54.5%, and the overall survival rate was 50.7%.
Induction chemotherapy was associated with improvements in disease-free, failure-free, relapse-free, and progression-free survival.
Obinutuzumab plus chemotherapy improved progression-free survival and time to next treatment.
Researchers identified demographic and socioeconomic factors associated with differences in staging of non-small cell lung cancer at initial presentation.
The expanded approval was based on data from the phase 3 TRANSFORM and phase 2 PILOT studies.
The arsenic level in drinking water was negatively associated with incidences of lymphoma and leukemia in men and women.
A large cross-sectional study offered a survey of long COVID symptoms in children who have been infected with SARS-CoV-2.
Having a high-deductible health plan was associated with a nearly 5-month delay in the diagnosis of metastatic cancer.
The pooled incidence of chemoradiation-induced grade 3-5 pneumonitis was 3.62% in randomized trials, 5.98% in observational studies, and 7.85% in observational studies of platinum doublet chemotherapy.
Patients who received denosumab had a significant improvement in disease-free survival and bone metastasis-free survival.
African-American patients were more likely to be eligible for lung cancer screening using USPSTF’s 2021 criteria vs 2013 criteria.
Researchers sought to identify factors that increase the risk of developing breast cancer-related lymphedema in patients who underwent axillary lymph node dissection.
The accelerated approval was based on data from two phase 2 trials: the ROAR basket study and the NCI-MATCH Subprotocol H study.
The combined SARS-CoV-2 seroprevalence from infection or vaccination reached an estimated 94.7% by December 2021.
Research has revealed patterns of opioid use and misuse in cancer patients and survivors.
The prevalence of pregnancy with cancer increased 13.8% from 2016 to 2019.
Two treatment-related factors and the frequency of 6 cell types were associated with response to COVID-19 vaccination.
The association does not hold for nondairy calcium intake.
Patients on dialysis die from cancer at twice the rate as those of the same age and sex in the general population, a study found.
Findings persist across racial/ethnic groups, regardless of government or private insurance, and across facility types.
Researchers compared Medicare Part D spending for 89 drugs to prices for their generic equivalents sold by Mark Cuban Cost Plus Drug Company.
Researchers assessed the association between dexamethasone treatment and the occurrence of superinfections among patients with severe COVID-19.
Researchers are conducting a phase 1 trial of nab-paclitaxel and pembrolizumab in patients with hormone receptor-positive breast cancer.
Researchers are conducting a phase 1 trial to evaluate RGT-419B, a CDK2/4/6 inhibitor, in patients with HR+, HER2-, stage III/IV breast cancer.
Researchers are conducting a phase 2 trial to determine if adding simvastatin to dual anti-HER2 therapy will induce a response after progression of HER2+ metastatic breast cancer.
Researchers aim to determine if ctDNA testing can guide second-line adjuvant therapy in high-risk, stage II-III, ER+, HER2- breast cancer.
Vitamin E does not decrease the risk of cancer or cancer-related death, and the risk of harm from beta carotene outweighs any potential benefits, according to the USPSTF.
The incidence of advanced lung cancer declined by 3 cases per 100,000 people per year in 2015-2018 relative to 2004-2014.
The overall response rate was 66.7%, and the median duration of response was 17.5 months.
The rate of progression to anal cancer was lower for patients receiving treatment for anal high-grade squamous intraepithelial lesions.
Only 5.7% of hospitals met both requirements, which are a machine-readable file for required price types and an accessible display for at least 300 shoppable items.
Numbers of new patient accruals and newly activated trials decreased early on, followed by a progressive recovery and return to levels that were higher than normal.
Researchers assessed the safety and immunogenicity of Nanocovax, a novel COVID-19 vaccine candidate.
Among patients with ER+/HER2+ breast cancer, the median survival after distant recurrence increased from 2.3 years in 2000 to 4.8 years in 2019.
Acupuncture was associated with improvements in symptoms and quality of life.
The cumulative incidence of obesity-related cancers at 10 years was 2.9% in the bariatric surgery group and 4.9% in the nonsurgical control group.
In its ruling, the court challenged the Trump-era finding that glyphosate was not a serious health risk and “not likely” to cause cancer.
Use of digital breast tomosynthesis was associated with a lower risk of advanced breast cancer for certain patients.
The study evaluated Paxlovid in both vaccinated and unvaccinated patients with COVID-19 at standard risk for progressing to severe disease.
There was no significant difference in survival outcomes with trabectedin or physician’s choice of chemotherapy.
The FDA received licensing applications sooner and had shorter review times, compared to the European Medicines Agency.
Rivoceranib produced responses whether or not patients had received prior treatment with a VEGFR TKI.
Higher total fish intake, tuna intake, and nonfried fish intake were all positively linked to the risk of malignant melanoma and melanoma in situ.
Researchers sought to define clinical and prognostic features associated with fever of unknown origin in patients later diagnosed with lymphoma.
There was an increased risk of new-onset type 2 diabetes in patients with pancreatic, brain/central nervous system, endometrial, lung, urinary tract, and breast cancers.
There was a higher risk for DLLR seen among women and among individuals aged 30 to 69 years.
Researchers are conducting a phase 1/2 trial to assess the safety and efficacy of combination repotrectinib, irinotecan, and temozolomide.
Researchers are conducting a phase 1 trial to assess the safety and efficacy of RRx-001 in combination with irinotecan and temozolomide.
Researchers are conducting a phase 1 trial of ibrutinib plus indoximod, cyclophosphamide, and etoposide in patients with brain cancers.
Researchers will assess toxicity and pharmacokinetics in phase 1 and the antitumor activity of nivatrotamab in phase 2.
Patients trust that what they tell their doctors will remain confidential, but under certain specific circumstances, the doctors may be obligated to breach that trust.
Replacing sugar-sweetened beverages with water and non-sugar-sweetened coffee or tea could significantly lower liver cancer risk, researchers said.
Discriminatory policies, systemic inequities, and structural barriers resulting from the history of racism cause and perpetuate cancer health disparities.
Adherence to a healthful plant-based food diet is associated with a reduced risk of breast cancer for postmenopausal women, a study suggests.
Biopsy of nontumor sites after initial colorectal cancer biopsy was not linked to a risk for metachronous cancer.
While mammography, biopsies, and cancer diagnoses are up from 2020 lows, none have reached pre-COVID-19 volumes.
The estimated 2-year RFS rate for patients with MPR was 93.3% (95% CI, 87.2%-99.9%) after a median follow-up of 27.9 months.
Among patients receiving 2 doses, peak vaccine efficacy against symptomatic COVID-19 was estimated to be 94.1% at 120 days after the first dose.
The study population included patients aged 18 years and older who had histologically confirmed desmoplastic melanoma that was resectable.
The 3-drug strategy combines targeted therapy against BRAF (vemurafenib) and MEK (cobimetinib), and immunotherapy (atezolizumab).
Patients were stratified by programmed death ligand 1 status and randomly and evenly assigned to 3 treatment groups.
In all, 32 patients had a response, translating to an ORR of 66.7%.
Patients with sonic hedgehog medulloblastoma and Li-Fraumeni syndrome have a “dismal” prognosis, according to researchers.
The overall response rate after 2 treatment cycles was 78%.
Among the TEAEs of clinical interest, the most frequent were infections, bleeding, cardiac events, anemia, and neutropenia and neutrophil count decrease.
Parsaclisib is a potent, highly selective, next-generation phosphoinositide 3-kinase-delta (PI3K-delta) inhibitor.
Based on preliminary data from this study, sugemalimab was granted breakthrough therapy designation for adult patients with R/R ENKTL in 2021.
At a median follow-up of 12.6 months, the overall response rate was 51.6% and the CR rate was 39.4%.
Results of a phase 3 trial suggest that brentuximab vedotin (Bv) with doxorubicin (A), vincristine (V), etoposide (E), prednisone (P), and cyclophosphamide (C) should be the new standard frontline therapy among youth with high-risk classic Hodgkin lymphoma (cHL).
RNA sequencing confirmed the alterations most frequently described in low-grade glioma and revealed rare gene fusions.
Of the patients who completed follow-up, 60% had a targeted therapy recommendation.
The median duration of response was not reached at a median follow-up of 26 months.
The patients were randomly assigned 2:1 to asciminib 40 mg twice daily or bosutinib 500 mg once daily.
The percentage of patients with stage I disease increased from 23.5% in 2010 to 29.1% in 2017.
The investigators performed univariate and multivariate analyses to identify factors associated with the loss of MMR.
The overall response rate was 33%, with 1% of patients having complete responses and 32% having partial responses.
Results showed a median overall survival of 25.0 months for chemo-immunotherapy vs 20.9 months for immunotherapy alone.
The researchers noted that responses were deep, with 75% of responders achieving a greater than 50% tumor reduction.
TACTI-002, enrolled 114 patients with untreated locally advanced or metastatic non-small cell lung cancer, unselected for PD-L1 expression.
In CML, second malignancies are rare and trends remain poorly understood.
From 2017 to 2019, the number of beneficiaries prescribed at least 1 oral TKI increased from 154 beneficiaries to 212 beneficiaries.
Investigators reported findings from the ongoing SARS2 SeroPrevalence And Respiratory Tract Assessment (SPARTA) study.
Of the 65 patients who achieved a complete remission with chemotherapy, 63 remained in remission after whole ventricular radiotherapy and at the final follow-up.
The treatment proved noninferior to cisplatin-based radiochemotherapy.
There was no significant difference in rates of secondary neoplasms at 10 years.
Metastatic relapse was associated with elevated tumor markers, but it was not associated with focal or whole ventricular radiotherapy.
Hispanic and non-Hispanic patients had a similar risk of death.
Extended decitabine produced a similar overall survival rate as standard chemotherapy, but decitabine had a better safety profile.
Axi-cel improved event-free survival vs standard care in older patients with relapsed/refractory large B-cell lymphoma.
Patients with previously untreated CLL had superior PFS with fixed duration venetoclax plus obinutuzumab, with or without ibrutinib.
A global survey of health care providers revealed significant knowledge gaps about childhood central nervous system tumors.
Medulloblastoma survivors had an increased risk of long-term adverse outcomes.
Use of radiation decreased over time, while use of surgery alone increased.
The etiology of comorbidities depends on hypothalamic tumor location and treatments received.
Nivolumab alone or in combination with ipilimumab did not improve outcomes compared with historical data.
Overall, there was no improvement in complete response or survival outcomes among patients who received bortezomib.
The overall response rate at cycle 4 was 61.5%, and none of these patients relapsed.
The 2 regimens produced similar efficacy outcomes, but adverse events were more common in the R-CODOX-M/R-IVAC arm.
Results from the phase 3 QuANTUM-First trial have the potential to change standard care for adults with newly diagnosed FLT3-ITD+ acute myeloid leukemia, according to the lead study author.
The overall response rate was 100%, and the 18-month progression-free survival rate was 53%.
Load More